KalVista Pharmaceuticals to be Acquired by Chiesi Group for $1.9 Billion in All-Cash Deal

summarizeSummary

KalVista Pharmaceuticals has entered into a definitive agreement to be acquired by Chiesi Group for $27.00 per share in cash, valuing the company at approximately $1.9 billion.

check_boxKey Events

• Definitive Merger Agreement Signed

  KalVista Pharmaceuticals has entered into an Agreement and Plan of Merger with Chiesi Farmaceutici S.p.A. and its subsidiary, Skyline Merger Sub, Inc.

• All-Cash Acquisition at Premium

  Chiesi will acquire all outstanding shares of KalVista for $27.00 per share in cash, representing an approximate total equity value of $1.9 billion. This price offers a 36% premium to KalVista's 30-day volume-weighted average share price as of April 28, 2026, and is above the 52-week high of $21.305.

• Board Unanimously Approves Transaction

  The Boards of Directors of both Chiesi and KalVista have unanimously approved the acquisition.

• Expected Closing in Q3 2026

  The transaction is anticipated to close in the third quarter of 2026, subject to customary closing conditions, including the tender of a majority of outstanding shares and regulatory approvals (HSR Act, Germany, Italy).

auto_awesomeAnalysis

This 8-K filing officially announces the definitive agreement for Chiesi Group to acquire KalVista Pharmaceuticals. The all-cash offer of $27.00 per share represents a significant premium over the current trading price and is notably above the company's 52-week high of $21.305, providing immediate and substantial value to shareholders. The transaction, valued at approximately $1.9 billion, is a major positive development for shareholders, offering immediate liquidity and a substantial return. The acquisition is not subject to a financing condition, reducing execution risk, and is expected to close in Q3 2026, pending regulatory approvals and majority share tender.